Condition
Neuronal Ceroid Lipofuscinosis Type 2
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Active Not Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT05152914Phase 1Active Not RecruitingPrimary
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2
NCT05791864Phase 1RecruitingPrimary
A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
Showing all 2 trials